A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies

Trial Profile

A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs BMS 986158 (Primary) ; Nivolumab
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms BET
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 13 Feb 2018 Nivolumab drug has been added in the study hence treatment arms has changed.
    • 13 Feb 2018 Planned End Date changed from 17 Dec 2018 to 3 Dec 2021.
    • 13 Feb 2018 Planned primary completion date changed from 16 Dec 2018 to 2 Dec 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top